US 10752623
Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors
granted A61PA61P25/08
Quick answer
US patent 10752623 (Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors) held by Xenon Pharmaceuticals Inc. expires Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Xenon Pharmaceuticals Inc.
- Grant date
- Tue Aug 25 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 20 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 38
- CPC classes
- A61P, A61P25/08